Infliximab-induced optic neuritis

BMJ Case Rep. 2020 Dec 22;13(12):e236041. doi: 10.1136/bcr-2020-236041.

Abstract

Antitumour necrosis factor alpha agents are important treatments in many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis and the inflammatory bowel diseases. However, there have been case reports of optic neuritis and other demyelinating diseases as complications of these agents. This case report presents a patient with ulcerative colitis on infliximab who presented with sudden onset mono-ocular visual field loss and highlights the diagnosis and management of infliximab-induced optic neuritis.

Keywords: biological agents; drugs: CNS (not psychiatric); inflammatory bowel disease; neuroopthalmology; visual pathway.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Blindness / diagnosis
  • Blindness / drug therapy
  • Blindness / immunology*
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology
  • Drug Substitution
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Infliximab / adverse effects*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Optic Nerve / diagnostic imaging
  • Optic Nerve / drug effects
  • Optic Nerve / immunology
  • Optic Neuritis / complications
  • Optic Neuritis / diagnosis
  • Optic Neuritis / drug therapy
  • Optic Neuritis / immunology*
  • Prednisolone / therapeutic use
  • Tomography, Optical Coherence
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology
  • Visual Acuity
  • Visual Field Tests
  • Visual Fields

Substances

  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • Prednisolone
  • vedolizumab
  • Infliximab